Xcipro

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Xcipro

Property Description
Active ingredient Ciprofloxacin (or Ciprofloxacin hydrochloride)
Form Tablet, Suspension, Injectable, Ophthalmic solution/ointment
Pharmacological class Fluoroquinolone Antibiotic
Common use Treatment of bacterial infections
Origin Synthetic

Xcipro is a trade name for the medication containing the active ingredient Ciprofloxacin, a powerful, synthetic substance widely recognized in medical practice for its ability to resolve bacterial infections throughout the body. Its identity is defined by its role as a potent antimicrobial agent that addresses a wide spectrum of susceptible bacteria. Ciprofloxacin is classified as a prescription-only medicine, underscoring its focused clinical utility.


What Type of Medicine is Xcipro (Ciprofloxacin)?

Ciprofloxacin is categorized as a fluoroquinolone antibiotic, which is a specialized pharmacological class of drugs known for their synthetic origin and broad effectiveness. This class is used in managing a wide array of infections caused by susceptible pathogens, including those that may be resistant to other antibiotic classes. The medication provides a broad-spectrum capability, meaning it is effective against a diverse and extensive range of bacterial types, making it a critical therapeutic agent for resolving microbial challenges.


Composition and Available Forms

The medication is a single-ingredient product, containing only Ciprofloxacin (or its salt form, Ciprofloxacin hydrochloride), combined with essential non-active ingredients in its base or vehicle. This active ingredient is presented in multiple dosage forms to suit different clinical needs, including tablets and oral suspension for systemic absorption, as well as specialized injectable solutions and ophthalmic solutions or ointments for targeted, localized application to the eye. This differentiation in form ensures the active ingredient can be effectively administered, whether via the oral route for systemic effects or the ophthalmic route for precise localized action.


How Does Ciprofloxacin Work Generally?

Ciprofloxacin works by a bactericidal action, meaning it actively kills the harmful bacteria causing the infection rather than simply inhibiting their growth. This effect is achieved because Ciprofloxacin directly interferes with the bacteria’s DNA, blocking the essential enzymes—DNA gyrase and Topoisomerase IV—that are required for the microorganisms to copy, repair, and manage their genetic material. This efficient and targeted disruption of bacterial integrity leads to the direct elimination of the infectious source, providing the general therapeutic benefit of rapidly resolving bacterial proliferation.

What side effects are possible with Xcipro?

Xcipro: Possible side effects and safety information

Adverse Reaction Categories

Regulatory authorities mandate a Boxed Warning for serious, disabling, and potentially irreversible adverse reactions associated with fluoroquinolones, including Xcipro. These serious adverse reactions can involve multiple body systems and may occur during treatment or months after discontinuation. They include:

  • Tendinitis and Tendon Rupture: This risk is higher in patients over 60 years old, those using corticosteroids, or those with solid-organ transplants. Rupture most frequently affects the Achilles tendon.
  • Peripheral Neuropathy: Symptoms of nerve damage, such as pain, burning, tingling, numbness, or weakness in the extremities, may be irreversible.
  • Central Nervous System Effects: Reactions may include seizures, tremors, anxiety, confusion, hallucinations, or suicidal thoughts/actions.

Other Serious and Clinically Significant Risks

Other serious adverse reactions documented in regulatory sources include:

  • Aortic Aneurysm and Dissection: Increased risk, particularly for elderly patients.
  • Hypersensitivity Reactions: Acute reactions, sometimes fatal (e.g., anaphylaxis, serious skin reactions).
  • Hepatotoxicity: Liver injury, sometimes fatal.
  • Clostridioides difficile-Associated Diarrhea: Can range from mild diarrhea to fatal colitis.
  • QT Interval Prolongation: A potential risk for a serious heart rhythm disorder.
  • Exacerbation of Myasthenia Gravis: May worsen muscle weakness and must be avoided in patients with a known history of this condition.

Common Adverse Reactions (FDA Clinical Trials)

Adverse reactions reported in clinical trials occurring at a frequency of ge 2% include nausea, headache, dizziness, diarrhea, vomiting, and vaginal moniliasis.

Population and Safety Restrictions

Due to the risk of musculoskeletal disorders and arthropathy seen in juvenile animals, use in pediatric patients is generally restricted. Geriatric patients face an increased risk for severe tendon disorders. Xcipro is contraindicated in patients with known hypersensitivity to the drug or other fluoroquinolones, and in patients taking Tizanidine. Caution is required in patients with known QT prolongation or uncorrected hypokalemia/hypomagnesemia.

Regulatory Safety Summary

Official safety guidance recommends that Xcipro be reserved for use in patients with certain uncomplicated infections only when no alternative treatment options are available. Treatment must be discontinued immediately if any signs of the serious adverse reactions noted in the Boxed Warning appear.

Overdose and Emergency Response

Overdose Scope

Element Official Regulatory Statement
Documented Manifestations Exaggerated Central Nervous System (CNS) effects, including seizures, confusion, and tremor; severe gastrointestinal disturbances; and findings of crystalluria and haematuria (blood in the urine).
Physiological Systems Affected Renal (potential for acute renal failure), Central Nervous System, and Cardiovascular (risk of QT prolongation).
Emergency Actions Required Seek immediate medical attention and contact a poison control center upon known or suspected overdosage.

Management and Constraints

Element Official Regulatory Statement
Severity Classification Overdosage carries the potential for severe outcomes, including acute renal failure and life-threatening ventricular arrhythmias (Torsades de pointes).
Antidote Information No specific antidote is known for Ciprofloxacin overdosage; treatment is defined as symptomatic and supportive.
Procedural Measures Management may include gastric emptying (e.g., gastric lavage) and administration of activated charcoal to limit absorption. Patients must be kept well hydrated to mitigate the risk of crystalluria.
Dialysis Note Only a small quantity of Ciprofloxacin (less than 10%) is removed by haemodialysis or peritoneal dialysis.

Connection to the Official Overdose Profile

The regulatory documents define the overdose profile by focusing on high-risk systemic effects, particularly acute renal failure and severe CNS and cardiac toxicity. This risk assessment mandates an immediate directive to seek emergency medical attention and prescribes a structured management approach based on supportive care, monitoring, and procedural decontamination.

Therapeutic Uses of Xcipro

This medication is applied across domains where additional symptomatic support is needed for bacterial infections.

Targeting Complicated Systemic and Genitourinary Infections

This agent is relevant in clinical settings that involve acute or unstable symptom patterns. It is considered relevant in conditions presenting with acute episodes of systemic imbalance, and relevant in conditions where symptoms may intensify temporarily in specific organs, such as the kidneys (pyelonephritis), bone and joints, or during high-risk scenarios like anthrax exposure. The agent supports the patient during difficult episodes by addressing symptoms related to physical discomfort, which helps maintain a sense of stability when symptoms are more noticeable.

Supporting Symptomatic Relief in Various Acute Bacterial Episodes

The medication is relevant when supportive symptom management is appropriate for conditions marked by increased physiological stress. These conditions include severe bacterial infections, and it is relevant in conditions presenting with systemic or localized discomfort, such as severe bacterial diarrhea or pneumonia, and conditions involving inflammatory or irritative processes in the eye and ear. This application supports the patient during difficult episodes by easing distress during symptomatic phases and provides support that helps ease the overall symptom burden.

Quick Fact: Management for Systemic Discomfort The therapeutic benefit is associated with managing symptoms related to systemic imbalance and heightened physiological activity, and is applied when appropriate when short-term symptomatic assistance is needed to ease the overall symptom burden.

Regulatory References

  1. NIH StatPearls Overview of Ciprofloxacin Uses

Eligibility and Restrictions for Use

Xcipro (Ciprofloxacin) eligibility is strictly defined by regulatory guidelines based on age, co-medication, and pre-existing health conditions.

Contraindications and Absolute Prohibitions

Use is contraindicated and strictly prohibited for individuals with a known hypersensitivity or allergy to Ciprofloxacin, any other fluoroquinolone antibiotic, or any component of the formulation. It must also not be used concurrently with the drug tizanidine, as this combination is an absolute prohibition mandated by regulatory labeling.


Age and Specific Population Restrictions

The medicine is generally approved for use in adults (18 years and older). Systemic use in children and adolescents is restricted to specific, severe infections (e.g., complicated urinary tract infections, anthrax exposure). Safety and efficacy are generally not established for infants under one year of age. Use in older adults carries an increased risk for certain adverse reactions.


Conditional Use and Limitations

Use must be avoided in patients with a history of myasthenia gravis, a known QT interval prolongation (a specific heart rhythm abnormality), or a history of tendon disorders related to quinolones. Patients with reduced kidney function (renal impairment) are eligible but require a formal dosage adjustment. Use during pregnancy and lactation is generally not recommended.

What should I know about interactions with other medicines?

Ciprofloxacin interactions are formally documented across metabolic, absorption, and pharmacodynamic domains.

Contraindications and Metabolic Effects

Co-administration with Tizanidine is contraindicated in regulatory documents. This severe interaction results from Ciprofloxacin acting as a potent inhibitor of the CYP1A2 enzyme, which significantly increases Tizanidine's plasma concentration and risk of adverse effects. This same CYP1A2 inhibition reduces the clearance of other substrates, leading to elevated exposure of drugs such as Theophylline and Caffeine. Co-administration with Probenecid is also documented to increase Ciprofloxacin concentration by reducing its renal clearance.

Absorption and Timing Restrictions

Multivalent cation-containing products, including antacids (aluminum/magnesium), Sucralfate, iron, and zinc supplements, significantly reduce Ciprofloxacin absorption through chelation. To mitigate this, Ciprofloxacin must be administered at least two hours before or six hours after these products. The consumption of dairy products or calcium-fortified juices alone is also officially discouraged.

Pharmacodynamic and Monitoring Notes

Avoidance is required for co-administration with other medicinal products known to prolong the QT interval. The anticoagulant effect of Warfarin may be enhanced, necessitating careful monitoring. Additionally, the risk of severe tendon disorders is increased in the elderly population when Ciprofloxacin is taken with corticosteroids.

Mechanism of Action

Targeting Bacterial Genomic Integrity

Ciprofloxacin acts by inhibiting two essential bacterial enzymes, DNA Gyrase and Topoisomerase IV, which are required for managing the bacterial cell’s DNA. By trapping these enzymes while they are bound to the DNA, the drug causes significant double-stranded DNA breaks, resulting in a direct bactericidal (killing) action. This molecular interference stops the bacteria from replicating their genetic material or dividing into new cells.

Overcoming Evolved Resistance Mechanisms

The mechanistic activity of Ciprofloxacin is constrained by two main bacterial defense mechanisms: target modification and active efflux. Bacteria can develop mutations in the enzyme targets that reduce the drug's binding affinity, or they can use efflux pumps to actively expel the Ciprofloxacin molecule from the cell. These mechanisms prevent the drug from maintaining the intracellular concentration necessary to generate DNA breaks, which attenuates the mechanism's destructive action at the cellular level.

Dosage and Administration Information

Xcipro (ciprofloxacin) administration is standardized across its multiple forms and routes. The medication is available for oral intake (as immediate-release or extended-release tablets and suspension), intravenous (IV) infusion for systemic use, and topical delivery via ophthalmic and otic preparations.

Oral dosing typically ranges from 250 mg to 750 mg every 12 hours for immediate-release tablets, while the extended-release tablets are taken once daily (q24h). Intravenous doses range from 200 mg to 400 mg and must be administered as a slow infusion over 60 minutes to minimize local adverse effects. The overall treatment duration is indication-specific, varying from 3 days for certain uncomplicated infections up to 60 days for complex post-exposure regimens.

Specific preparation and timing rules are essential for proper use. Oral forms must be strictly separated from all products containing polyvalent cations, such as dairy foods, antacids, or mineral supplements, by at least two hours before or six hours after administration. Furthermore, the dose and interval require modification for adult patients with impaired renal function (Creatinine Clearance le 50 mL/min), as an adjustment to prevent drug accumulation. Extended-release tablets must be swallowed whole and cannot be crushed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Xcipro (Ciprofloxacin)

The research evidence for Ciprofloxacin comes from a large body of studies, primarily Randomized Controlled Trials (RCTs). This overview describes what the research has explored and what the existing data suggest, while maintaining a focus on the limits and uncertainties documented in scientific literature.


Evidence for Use in Complicated Urinary Tract and Kidney Infections (cUTI/Pyelonephritis)

For infections in the urinary tract, Ciprofloxacin was studied for how patients fared over short treatment periods. Research examined the resolution of clinical signs and symptoms (clinical success) and the ability to eliminate the specific bacteria (bacteriological eradication). Studies comparing Ciprofloxacin to other established antibiotic options reported measurements of symptom resolution and bacterial clearance in the observed adult populations. The research so far indicates patterns of consistent findings when Ciprofloxacin was observed in trials exploring short-term outcomes in susceptible infections.

However, the growing trend of bacterial strains showing decreased susceptibility (resistance) to Ciprofloxacin is a key limitation in this area, which may impact the reliability of older study findings. This growing trend presents an uncertainty regarding the continued applicability of older study results.


Evidence in Special Populations (Children and Patients with Comorbidities)

Ciprofloxacin was evaluated in pediatric patients (children ages 1 to 17 years) specifically for complicated urinary tract infections. These clinical trials included a mandatory long-term observational follow-up to monitor specific safety concerns, such as musculoskeletal events. Comparative studies reported similar short-term clinical and bacteriological outcomes to control regimens.

Research also describes patterns related to Ciprofloxacin use in patients with other health challenges, such as impaired kidney function. These Pharmacokinetic (PK) studies were conducted to monitor how the drug concentration may change in people whose bodies process the medicine differently.


Key Research Gaps and Uncertainties

While there is a large volume of research, data are still emerging in several key areas. Comparative evidence is lacking in some areas, particularly large-scale trials comparing Ciprofloxacin to other specific antibiotic classes for all conditions. For complex, chronic conditions like bone infections, evidence quality varies across studies because the sample sizes were modest. Long-term effects are not fully established for most indications beyond immediate symptom resolution.

Frequently Asked Questions (FAQ)

Common questions about Xcipro (FAQ)


Q: Does Xcipro make your skin more sensitive to the sun?

A: Yes, official regulatory information indicates that Xcipro can cause a condition called photosensitivity, which is an increased sensitivity to sunlight. This means the skin may be more susceptible to sunburn. Due to this risk, the official label information notes that avoiding or limiting exposure to excessive sunlight and artificial UV light may be necessary while using this medication.


Q: Can Xcipro cause changes in mood or anxiety levels?

A: Yes, regulatory information lists anxiety, confusion, depression, hallucinations, and suicidal thoughts/actions as possible Central Nervous System (CNS) effects associated with this medicine. These effects may occur even after the first dose. The potential for these changes is noted in the official regulatory warnings.


Q: Can I take Xcipro if I have a history of kidney problems?

A: Yes, the medication can be used in patients with reduced kidney function (renal impairment). However, the regulatory labeling states that dosage modification is typically required to prevent the drug from accumulating to unsafe levels in the body.


Q: Can Xcipro be taken with antacids, or do I need to space them out?

A: Regulatory documents state that these products should be spaced out. Products containing polyvalent cations, such as aluminum/magnesium antacids, significantly reduce Xcipro’s absorption into the body. Official patient information states that Xcipro must be administered at least two hours before or six hours after these products.


Q: Is Xcipro similar to Levaquin, and how are they different?

A: Xcipro (ciprofloxacin) and Levaquin (levofloxacin) are similar because they both belong to the same fluoroquinolone antibiotic class and share a common mechanism for fighting bacteria. However, they are distinct chemical compounds, and they may be used to treat different specific infections, as indicated in their respective regulatory documents.


Q: Why is it important to finish the whole course of Xcipro even if I feel better?

A: Finishing the full prescribed course helps ensure the complete elimination of the targeted bacteria. Public health guidance emphasizes that stopping the medication too soon may increase the risk of the infection returning, and it contributes to the development of antibiotic resistance.


Q: Can Xcipro interact with common over-the-counter pain relievers like ibuprofen?

A: Regulatory guidance advises caution when taking Xcipro with non-steroidal anti-inflammatory drugs (NSAIDs), a class that includes ibuprofen. Official warnings state this combination may potentially increase the risk of central nervous system stimulation and could lead to seizures.


Q: Is Xcipro effective against the most common superbugs?

A: Xcipro is generally effective against a broad range of susceptible bacteria. However, official regulatory documents note a significant and growing trend of bacterial strains showing decreased susceptibility (resistance) to Xcipro, which may impact its effectiveness against certain highly resistant bacteria.


Q: What is the shortest time people usually take Xcipro for a simple infection?

A: Treatment durations are strictly based on the specific type of infection being addressed. The product label indicates treatment courses for some uncomplicated infections, such as acute uncomplicated cystitis, may be as short as three days.


Q: Can Xcipro cause joint pain, and is that a common side effect?

A: Yes, joint pain (arthralgia) has been reported in patients taking Xcipro. The medication’s Boxed Warning highlights the risk of more severe musculoskeletal events, including tendinitis and tendon rupture. The potential for these events is noted in the official regulatory warnings.


Q: Does Xcipro affect sleep, or is insomnia a potential side effect?

A: Yes, regulatory safety information indicates that Central Nervous System effects, including insomnia (difficulty sleeping) and restlessness, have been reported by people using this medicine.


Q: What kind of infections is Xcipro most effective at treating?

A: Xcipro is a broad-spectrum antibiotic approved for treating a wide variety of infections. The common FDA-approved uses include infections of the urinary tract, lower respiratory tract, skin and soft tissue, bone and joint, and certain types of infectious diarrhea.


Q: Why do doctors prescribe Xcipro instead of penicillin for some infections?

A: Xcipro is prescribed because it belongs to a different antibiotic class (fluoroquinolone) than penicillin. It has a broader range of activity and is effective against certain bacterial strains that have developed resistance to penicillin and other antibiotics.


Q: Does Xcipro have a generic version, and is it as effective?

A: Yes, the active ingredient, Ciprofloxacin, is widely available as a generic medication. The FDA considers generic versions to be therapeutically equivalent to the brand-name product, meaning they are expected to work the same way in the body.


Q: What happens if I miss a dose of Xcipro?

A: Official patient information generally addresses missed doses with specific timing rules based on the proximity of the next scheduled dose. For immediate-release tablets, the information often states that if the next dose is due soon (e.g., within six hours), the missed dose may need to be skipped. The guidance emphasizes that the total dose for the day should not be doubled.


Q: Is it normal to feel a bit nauseous when first starting Xcipro?

A: Nausea is a well-documented and common adverse reaction listed in the official clinical trials data for this medication. It is one of the more frequently reported side effects when first starting Xcipro.


Q: How long does Xcipro stay in your system after you stop taking it?

A: According to the official pharmacokinetic information, the drug has an elimination half-life of approximately 4 to 6 hours in adults with normal kidney function. Based on this, the majority of the drug is generally cleared from the body within 20 to 30 hours after the last dose.


Q: Does Xcipro interact with caffeine, and should I limit coffee intake?

A: Official regulatory documents note that Xcipro is an inhibitor of the CYP1A2 enzyme in the body, which processes substances like caffeine. This inhibition may lead to elevated levels of caffeine in the blood.


Q: What's the typical time frame for side effects to appear after starting Xcipro?

A: Common side effects like nausea can begin soon after starting treatment. However, official safety warnings emphasize that serious effects, such as tendon rupture or nerve damage, can occur at any time during treatment or even months after stopping the drug.


Q: Do other people report feeling dizzy or lightheaded on Xcipro?

A: Yes, dizziness is listed among the most common adverse reactions reported in clinical trials, occurring at a frequency of 2% or greater. This feeling is a known side effect based on official data.


Q: Is Xcipro commonly prescribed for skin and soft tissue infections?

A: Yes, according to the official Indications and Usage section, the medicine is FDA-approved for the treatment of skin and soft tissue infections caused by susceptible strains of bacteria.


Q: Does the time of day matter when taking Xcipro?

A: The medicine is generally used on a consistent schedule, such as every 12 hours (twice daily), to maintain stable levels in the body. While specific timing rules apply to food and supplements, there are no explicit regulatory requirements mandating morning versus evening use.


Q: Can Xcipro affect blood sugar levels in non-diabetic people?

A: Yes, regulatory safety communications indicate that disturbances in blood sugar have been reported with this class of antibiotics. This includes serious low blood sugar (hypoglycemia), which has been reported in patients using fluoroquinolones, including those without a prior history of diabetes.


Q: Are there different formulations of Xcipro (e.g., tablet vs. suspension)?

A: Yes, Xcipro contains the active ingredient ciprofloxacin and is available in multiple formulations to suit different needs. These include immediate-release tablets, extended-release tablets, and an oral suspension for systemic use.


Q: Can Xcipro cause temporary changes in taste or smell?

A: Yes, postmarketing surveillance reports include occurrences of loss of taste (ageusia) or changes in taste (dysgeusia). These sensory changes are documented in the official adverse reaction data.


Q: Is Xcipro used to prevent infections in certain high-risk patients?

A: Yes, the medication is FDA-approved for post-exposure prophylaxis (prevention) of certain serious infections, such as after potential exposure to inhalational anthrax.

How should Xcipro be stored and disposed of?

Storage and Disposal of Xcipro (Ciprofloxacin)

Official regulatory documents define specific storage and disposal requirements for Ciprofloxacin to maintain its stability and ensure safety.

Storage Requirements

Ciprofloxacin tablets must be stored at controlled room temperature 25 C (77 F), with permitted temperature excursions between 15 C and 30 C. The oral suspension, once constituted, is stable for 14 days when stored at room temperature or refrigerated, but must not be frozen. Ciprofloxacin Injection requires protection from light.

Child Safety: All formulations must be kept out of the sight and reach of children and stored in the original container.

Disposal Instructions

Unused or expired Ciprofloxacin must be disposed of according to local and regulatory requirements. The product should not be discarded via wastewater or standard household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Xcipro found in:

A-Z Index: